Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) shot up 5.6% during trading on Monday. The company traded as high as C$7.50 and last traded at C$7.50. 1,107 shares were traded during trading, a decline of 48% from the average session volume of 2,115 shares. The stock had previously closed at C$7.10.
Devonian Health Group Stock Performance
The company has a market capitalization of C$20.86 million, a PE ratio of -3.33 and a beta of -0.35. The firm’s 50-day simple moving average is C$8.74 and its 200-day simple moving average is C$10.25. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Further Reading
- Five stocks we like better than Devonian Health Group
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
